Nevada hospitals and health clinics say drug manufacturers are restricting the number of pharmacies in the state that can ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

The 340B program allows certain nonprofit hospitals to buy prescription drugs at a significant discount. Larger urban hospitals generate most of the 340B revenue, while smaller rural clinics struggle ...

On December 29, 2025—just three days before the 340B Rebate Model Pilot Program (the Rebate Program) was set to begin—the U.S. District Court for the District of Maine issued an order granting a ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

The 340B Drug Discount Program was designed to help safety-net providers make drugs available to low-income patients and earn revenue. Drug manufacturers have put restrictions on which pharmacies ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

Federal complaints by University of Michigan, University of Kansas Hospital Authority, and Mount Sinai entities seek recovery of approximately $250 million in alleged 340B savings diversion from ...

The University of Kansas Hospital Authority is suing CVS Health for allegedly stealing 340B program savings. The lawsuit claims CVS's actions resulted in nearly $62 million in damages and losses for ...